Low CD34+ Cell Doses are Associated with Increased Cost and Worse Outcome Following of Tandem Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Germ Cell Tumors

• 23% of GCT patients collect a suboptimal number of PBSC for tandem ASCT using filgrastim• Low CD34+ cell doses are associated increased transplant costs and worse survival• Despite higher costs and worse outcome, low CD34 cell doses should not preclude ASCT

Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: Mustafa A. Hyder, W. Scott Goebel, Kirsten D. Ervin, Jennifer E. Schwartz, Michael J. Robertson, Teresa C. Thakrar, Costantine Albany, Sherif S. Farag Source Type: research